Marshall Wace LLP Takes $131,000 Position in InfuSystem Holdings, Inc. (NYSE:INFU)

Marshall Wace LLP acquired a new position in InfuSystem Holdings, Inc. (NYSE:INFU) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 19,247 shares of the company’s stock, valued at approximately $131,000.

A number of other large investors have also made changes to their positions in the business. Rhumbline Advisers boosted its holdings in InfuSystem by 13.8% in the second quarter. Rhumbline Advisers now owns 17,658 shares of the company’s stock valued at $121,000 after purchasing an additional 2,145 shares during the last quarter. Oppenheimer Asset Management Inc. raised its holdings in InfuSystem by 52.1% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 26,042 shares of the company’s stock valued at $178,000 after acquiring an additional 8,917 shares during the last quarter. Panagora Asset Management Inc. acquired a new stake in InfuSystem in the 2nd quarter valued at about $208,000. ARS Investment Partners LLC raised its holdings in InfuSystem by 11.4% in the 2nd quarter. ARS Investment Partners LLC now owns 33,510 shares of the company’s stock valued at $229,000 after acquiring an additional 3,422 shares during the last quarter. Finally, Perritt Capital Management Inc grew its stake in shares of InfuSystem by 169.4% in the 2nd quarter. Perritt Capital Management Inc now owns 38,500 shares of the company’s stock valued at $263,000 after buying an additional 24,207 shares during the period. 71.13% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

INFU has been the subject of a number of research analyst reports. B. Riley assumed coverage on shares of InfuSystem in a research report on Thursday, September 26th. They set a “buy” rating and a $13.00 price objective for the company. StockNews.com lowered shares of InfuSystem from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 28th.

InfuSystem Price Performance

Shares of INFU opened at $6.93 on Monday. The company has a current ratio of 2.07, a quick ratio of 1.64 and a debt-to-equity ratio of 0.64. The company has a market cap of $147.57 million, a P/E ratio of 693.69 and a beta of 1.46. InfuSystem Holdings, Inc. has a 1 year low of $5.74 and a 1 year high of $10.99.

InfuSystem (NYSE:INFU) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.01). The business had revenue of $33.70 million during the quarter. InfuSystem had a return on equity of 0.70% and a net margin of 0.28%. Sell-side analysts predict that InfuSystem Holdings, Inc. will post 0.17 earnings per share for the current year.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.